Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Blood (2022) 140 (8): 927–931.

https://doi.org/10.1182/blood.2022016642

Published: 2022

Includes: Supplemental data

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Blood (2021) 138 (Supplement 1): 2608.

https://doi.org/10.1182/blood-2021-150394

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Mesenchymal Stromal Cell (MSC) Compassionate Use in France in Treatment of Steroid-Refractory Graft-Versus-Host-Disease (GVHD) after Approval By the Expert Committee of Société Française De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Lea Bosdure, Resident, Laurence Blanc, MD, Nimrod Buchbinder, MD, Valerie Coiteux, MD, Gaelle Fossard, MD, Sylvie Francois, MD, Marie Ouachee, MD, Catherine Paillard, MD PhD, Cecile Pochon, MD, Arthur Sterin, MD MSc, Nadine Petitpain, PharmD, Jacques-Olivier Bay, MD PhD, Marie Thérèse Rubio, MD PhD, Danièle Bensoussan, Jean-Hugues Dalle, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142304

Published: 2020

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD

Blood (2017) 130 (Supplement 1): 2901.

https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901

Published: 2017

Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD

Blood (2016) 128 (22): 1894.

https://doi.org/10.1182/blood.V128.22.1894.1894

Published: 2016

Journal Articles

Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution

Herve Ghesquieres, MD PhD, Celine Segura-Ferlay, MS, Gaelle Fossard, MD, Francois Ducray, MD PhD, Violaine Safar, MD, Philippe Rey, MD, Emmanuelle Nicolas-Virelizier, MD, Catherine Sebban, MD, Amine Belhabri, MD, Pierre Biron, MD, Emmanuel Jouanneau, MD PhD, David Meyronnet, MD PhD, Catherine Chassagne-Clement, MD, Jerome Honnorat, MD PhD, Jean-Yves Blay, MD PhD

Blood (2015) 126 (23): 1544.

https://doi.org/10.1182/blood.V126.23.1544.1544

Published: 2015

Journal Articles

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Gaelle Fossard, MD, Emilie Blond, Pharm.D, Stephane Giraudier, MD PhD, Stephane Morisset, Stat., Jeremy Ruby, CRA student, Martine Escoffre-Barbe, MD, Hélène Labussière-Wallet, MD, Mael Heiblig, MD, Madeleine Etienne, CRA, Jocelyne Drai, Pharm.D, Mohamad Sobh, Pharm.M., Mauricette Michallet, MD PhD, Isabelle Redonnet-vernhet, MD PhD, Jean-christophe Lega, MD PhD, Gabriel Etienne, MD PhD, Franck E. Nicolini, MD PhD

Blood (2014) 124 (21): 3136.

https://doi.org/10.1182/blood.V124.21.3136.3136

Published: 2014

Journal Articles

Overall Management, Outcomes and Costs on a 4-Year Period of 21,757 Acute Leukemia (AL) Patients in France. Data Report from the National Health Registry

Franck E. Nicolini, MD PhD, Caroline Laurendeau, MSc, Isabelle Bureau, MSc, Jean-FranÃois Ricci, PharmD, PhD, Christophe Gerbeau, MD, Gaelle Fossard, MD, Mael Heiblig, MD, Stephane Bouee, MDMSc

Blood (2014) 124 (21): 1313.

https://doi.org/10.1182/blood.V124.21.1313.1313

Published: 2014

Journal Articles

Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse

Gaelle Fossard, MD, Emmanuelle Nicolas-Virelizier, MD, Philippe Rey, MD, Francois Ducray, MD, Emmanuel Jouanneau, MD, PhD, Pierre Faurie, MD, Amine Belhabri, MD, Marie Pierre Sunyach, MD, Catherine Chassagne-Clement, MD, Philippe Thiesse, MD, Catherine Sebban, MD, Pierre Biron, MD, Jean-Yves Blay, MD, PhD, Herve Ghesquieres, MD, PhD

Blood (2013) 122 (21): 933.

https://doi.org/10.1182/blood.V122.21.933.933

Published: 2013

NARROW

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Mesenchymal Stromal Cell (MSC) Compassionate Use in France in Treatment of Steroid-Refractory Graft-Versus-Host-Disease (GVHD) after Approval By the Expert Committee of Société Française De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Overall Management, Outcomes and Costs on a 4-Year Period of 21,757 Acute Leukemia (AL) Patients in France. Data Report from the National Health Registry

Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only